Fund profile

Civilization Ventures

San Francisco, United States

Leading

About

Civilization Ventures is a venture capital firm founded in 2017 with a strong focus on health tech and biology innovations. Based in Silicon Valley, the firm has grown from a $1M pilot seed fund to managing over $100M in capital. They have invested in over 60 companies across genomics, diagnostics, digital health, and synthetic biology, emphasizing preventative, personalized, and regenerative healthcare solutions. Notable investments include Rocket Pharma, which focuses on gene therapies for rare diseases, and Singular Bio, acquired by Invitae to enhance genetic screening in early pregnancy. Other significant exits include Lemonaid Health, acquired by 23andMe, and Rewrite, a gene editing company acquired by Intellia. The team at Civilization Ventures is composed of experienced biopharma executives and operators who have founded and sold companies. They support founders through a vast network and their extensive experience in the field. Additionally, they offer a unique fellowship program to train PhDs to become future entrepreneurs in the life sciences sector.

Details

Highlights

$4.9M

Historical average check

$144M

Historical max check

January 2025

Last investment date

61

Investments

Biotech

Healthtech & Wellness

Pharma

AI & Deep Tech

Data & Analytics

Funds that also invest in AI & Deep Tech